Brokerages Set Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Price Target at $8.33

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been given a consensus rating of “Moderate Buy” by the five research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.3333.

AUTL has been the subject of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Wells Fargo & Company dropped their price objective on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. Wall Street Zen lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, November 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers lifted its stake in Autolus Therapeutics by 47.3% during the 1st quarter. Cetera Investment Advisers now owns 524,872 shares of the company’s stock valued at $814,000 after acquiring an additional 168,650 shares during the period. Privium Fund Management B.V. raised its holdings in shares of Autolus Therapeutics by 8.6% during the first quarter. Privium Fund Management B.V. now owns 251,674 shares of the company’s stock worth $390,000 after purchasing an additional 20,000 shares during the last quarter. Invesco Ltd. lifted its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after purchasing an additional 11,381 shares during the period. Knott David M Jr acquired a new position in Autolus Therapeutics during the first quarter valued at $651,000. Finally, Wellington Management Group LLP boosted its holdings in Autolus Therapeutics by 6.9% in the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock valued at $41,992,000 after purchasing an additional 1,746,020 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock opened at $1.37 on Monday. The stock has a market cap of $364.61 million, a PE ratio of -1.65 and a beta of 1.84. The stock has a 50-day moving average of $1.49 and a two-hundred day moving average of $1.81. Autolus Therapeutics has a one year low of $1.11 and a one year high of $3.45.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.07). The company had revenue of $21.19 million for the quarter, compared to analyst estimates of $21.08 million. Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. As a group, sell-side analysts predict that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.